Edgen Stock·Dec 18 2025, 07:30Back
J&J Gains FDA Approval for Lung Cancer Drug Slashing Treatment Time to 5 Minutes
Edgen Stock·Dec 18 2025, 07:30
[1] U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib) (https://finance.yahoo.com/news/u-fda-approval ...)
